SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [**REDACTED**] and assuming the [**REDACTED**] is not exercised and no other changes are made to the issued share capital of our Company from the Latest Practicable Date to the [**REDACTED**], the following persons will have an interest or a short position in the Shares or the underlying Shares which will be required to be disclosed to our Company and the Stock Exchange pursuant to the provisions of Division 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company:

				As of the Latest Practicable Date	Immediately following completion of the [REDACTED]	
Name of Shareholder	**Nature of interest**	**Description of Shares**	**Number of Shares held**	**Approximate percentage of shareholding in our total Share capital(1)**	**Approximate percentage of shareholding in our A Shares**	**Approximate percentage of shareholding in our total Share capital**
NBP Pharmaceutical(2)	Beneficial owner	A Shares	1,037,058,294	73.83%	[**REDACTED**]%	[**REDACTED**]%
	Interest in controlled corporation	A Shares	11,587,212	0.82%	[**REDACTED**]%	[**REDACTED**]%
Dragon Merit(2)	Interest in controlled corporation	A Shares	1,048,645,506	74.66%	[**REDACTED**]%	[**REDACTED**]%
Robust Sun(2)	Interest in controlled corporation	A Shares	1,048,645,506	74.66%	[**REDACTED**]%	[**REDACTED**]%
CSPC Pharmaceutical(2)	Interest in controlled corporation	A Shares	1,048,645,506	74.66%	[**REDACTED**]%	[**REDACTED**]%

Notes:

(1) The calculation is based on the total number of 1,404,592,944 A Shares in issue (including 12,000,225 A Shares repurchased and held in our Company's stock repurchase account as treasury shares) as of the Latest Practicable Date.

(2) NBP Pharmaceutical is a beneficial owner of 1,037,058,294 Shares and is deemed to be interested in 11,587,212 Shares owned by its wholly-owned subsidiary CSPC Ouyi under the SFO. Further, NBP Pharmaceutical is owned as to 45.94% and 54.06% by Dragon Merit and CSPC Pharmaceutical, respectively. Dragon Merit is wholly owned by Robust Sun which is in turn wholly owned by CSPC Pharmaceutical. As such, each of Dragon Merit, Robust Sun and CSPC Pharmaceutical is deemed to be interested in the same number of Shares owned by NBP Pharmaceutical and CSPC Ouyi under the SFO.

Save as disclosed above, our Directors are not aware of any persons who will, immediately following completion of the [**REDACTED**] (assuming that the [**REDACTED**] is not exercised), have interests or short positions in Shares or underlying Shares which would fall to be disclosed under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company.